ASCO 2023 – Meet IDDI Oncology Experts

June 2, 2023 — June 6, 2023

Chicago, IL

Schedule a meeting with Dr Marc Buyse, ScD and Dr Everardo Saad, MD at ASCO 2023

We will be happy to discuss your next oncology drug development and optimize your clinical development strategy at ASCO Annual Meeting 2023.

MEET OUR EXPERTS

Marc Buyse, ScD, Chief Scientific Officer, IDDI

Marc holds a ScD in biostatistics from the Harvard School of Public Health (Boston, MA). He is the founder of the International Drug Development Institute (IDDI) and of CluePoints, two biostatistical service organizations based in the US and Europe. He is interested in clinical trial design, meta-analysis, validation of biomarkers and surrogate endpoints, statistical methods in oncology, statistical detection of errors and fraud, statistical monitoring of clinical trials, and medical data sharing.

Everardo Saad, MD, Medical Director, IDDI

Dr. Everardo Saad has nearly 20 years of experience in Medical Oncology and clinical-trial design. He graduated in Medicine and trained in Internal Medicine in Sao Paulo, and did his fellowship in Medical Oncology at the University of Texas M.D. Anderson Cancer Center, in Houston. After practicing for several years, he shifted his professional career towards education and research in Medical Oncology, and has a special interest in clinical trial methodology, the assessment of endpoints, and the development of novel therapies for cancer patients.

Leverage Our Oncology Expertise And Gain Efficiency In Your Oncology Trials​

• Our experts know the importance of keeping up to date with all the latest advances in the field of immunotherapy and oncology medicine thanks to our strong collaboration with KOL’s.
• Coming from a scientific background, IDDI is an oncology CRO led by a highly-skilled biostatistical and clinical team of thought-leaders in oncology research.
• IDDI’s expertise lies in the right choice of endpoints, adequate definition of selection criteria and state-of-the-art statistical planning, and analysis and modelling tailored to oncology drug development needs.
• Our valuable therapeutic insight in cancer research, paired with data quality expertise, will make a critical difference to the outcome of your clinical trials.

WE LOOK FORWARD TO MEETING YOU AT ASCO 2023 

ABOUT ASCO 2023

Join the global oncology community and discover the latest innovations in cancer science and innovations. If you are involved in the study, diagnosis and treatment of people with cancer cancer, you have to attend ASCO Annual Meeting 2023!